Provectus Pharmaceuticals Inc. (PVCT.OB) is a Tennessee-based development stage pharmaceutical company that specializes in oncology and dermatology therapies. Complementing the company’s lineup of proprietary drugs, Provectus has developed a number of intellectual properties and technologies in the areas of imaging, medical devices, and biotechnology.
In the biotechnology area, the company has developed groundbreaking technology to augment vaccine production and detect viruses. Another area that Provectus is focusing on is the dermatology space. The company is currently conducting Phase 2 clinical trials of their proprietary drug PH-10, to be used as a topical treatment for psoriasis and atopic dermatitis.
Provectus Pharma’s main focus however is in the treatment of cancer. The company is developing advanced therapies to target and destroy the deadliest cancers – melanoma, liver cancer, and breast cancer – while eliminating side effects. Clinical trials for treatment of metastatic melanoma and recurrent breast carcinoma with the company’s PV-10 drug are currently underway in Australia.
On July 7, 2008, Provectus announced that the first 25% of melanoma subjects in Australia have been treated in the company’s Phase 2 clinical trial of PV-10. If the results from these Phase 2 trials are as positive as the results were from the Phase 1 trial, the company expects to then ask the FDA for an accelerated approval. Provectus also expects to begin Phase 2 trials for PV-10 in the U.S. in the very near future.
Let us hear your thoughts below: